Zydus begins Phase-II trials for its new anaemia drug Zyan1

Developed drug, an oral molecule, is the latest new chemical entity from the firm's pipeline

Ahmedabad-based drug major Cadila Healthcare (Zydus Cadila) on Wednesday announced that it had initiated its second phase of trials to investigate Zyan1, an oral molecule used to treat anaemia associated with chronic kidney disease (CKD). 

The development comes from the company's new chemical entity (NCE) pipeline. Currently, Zydus Cadila has a pipeline of four NCEs, of which three are new and one is already under trial. The country's first NCE- Lipaglyn (Saroglitazar)- was developed in-house by Zydus. The drug is currently approved in India as the prescribed medicine for the treatment of hypertriglyceridemia and diabetic dyslipidemia. It is usually prescribed to